Davidson David Form 4 February 05, 2019

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Check this box if no longer subject to

Section 16.

Form 4 or Form 5 obligations may continue. See Instruction STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF **SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1(b).

(Last)

1. Name and Address of Reporting Person * **Davidson David**

> (First) (Middle)

C/O BLUEBIRD BIO, INC., 60 **BINNEY STREET**

(Street)

2. Issuer Name and Ticker or Trading Symbol

bluebird bio, Inc. [BLUE]

3. Date of Earliest Transaction (Month/Day/Year)

02/01/2019

4. If Amendment, Date Original Filed(Month/Day/Year)

OMB APPROVAL

OMB Number:

3235-0287

Expires:

January 31, 2005

Estimated average burden hours per

response...

0.5

Person

CAMBRIDGE, MA 02142

(City)	(State)	(Zip) Tak	ole I - Non-	-Derivativ	e Secu	ırities Acquir	ed, Disposed of,	or Beneficiall	y Owned
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	on Date, if Transaction Disposed of (D) Code (Instr. 3, 4 and 5) Day/Year) (Instr. 8) (A) or			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Common Stock (1)	02/01/2019		Code V A	Amount 9,375	(D)	Price \$ 0	31,616	D	
Common Stock	02/04/2019		M	3,555	A	\$ 24.47	35,171	D	
Common Stock	02/04/2019		M	1,355	A	\$ 50.51	36,526	D	
Common Stock	02/04/2019		S(2)	600	D	\$ 133.1311 (3)	35,926	D	
Common Stock	02/04/2019		S(2)	3,110	D	\$ 134.217 (4)	32,816	D	

Edgar Filing: Davidson David - Form 4

Common Stock $S_{\underline{(2)}}$ 1,200 D 135.1025 31,616 D

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474

(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of or Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Share
Stock Option (right to buy)	\$ 134.63	02/01/2019		A	37,500		<u>(6)</u>	02/01/2029	Common Stock	37,500
Stock Option (right to buy)	\$ 24.47	02/04/2019		M		3,555	<u>(7)</u>	03/03/2024	Common Stock	3,555
Stock Option (right to buy)	\$ 50.51	02/04/2019		M		1,355	(8)	03/01/2026	Common Stock	1,355

Reporting Owners

Reporting Owner Name / Address

Director 10% Owner Officer Other

Davidson David

C/O BLUEBIRD BIO, INC. 60 BINNEY STREET CAMBRIDGE, MA 02142

Chief Medical Officer

Reporting Owners 2

Signatures

/s/ Jason F. Cole, Attorney-in-Fact

02/05/2019

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Restricted stock units for common stock vest over a four-year period at a rate of 25% on 01/04/2020, 25% on 01/04/2021, 25% on 01/04/2022, and 25% on 01/04/2023.
- (2) The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on July 9, 2018.
 - The range in prices for the transaction reported on this line was \$132.62 to \$133.29. The average weighted price was \$133.1311. The
- (3) reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The range in prices for the transaction reported on this line was \$133.74 to \$134.66. The average weighted price was \$134.2170. The (4) reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- The range in prices for the transaction reported on this line was \$134.91 to \$135.42. The average weighted price was \$135.1025. The reporting person will provide, upon request by the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price.
- (6) This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 4, 2020 and in 36 equal monthly installments thereafter
- (7) This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 1, 2015 and in 36 equal monthly installments thereafter.
- (8) This option vests over a four-year period, at a rate of twenty-five percent (25%) on January 4, 2017 and in 36 equal monthly installments thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Signatures 3